- Home
- OCGN vs NGNE Comparison
OCGN vs NGNE Comparison
Compare OCGN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- NGNE
- Stock Information
- Founded
- OCGN 2013
- NGNE 2003
- Country
- OCGN United States
- NGNE United States
- Employees
- OCGN N/A
- NGNE N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- NGNE Health Care
- Exchange
- OCGN Nasdaq
- NGNE Nasdaq
- Market Cap
- OCGN 278.3M
- NGNE 251.9M
- IPO Year
- OCGN N/A
- NGNE N/A
- Fundamental
- Price
- OCGN $1.03
- NGNE $15.42
- Analyst Decision
- OCGN Strong Buy
- NGNE Strong Buy
- Analyst Count
- OCGN 3
- NGNE 7
- Target Price
- OCGN $6.00
- NGNE $41.86
- AVG Volume (30 Days)
- OCGN 8.5M
- NGNE 193.9K
- Earning Date
- OCGN 08-07-2025
- NGNE 08-08-2025
- Dividend Yield
- OCGN N/A
- NGNE N/A
- EPS Growth
- OCGN N/A
- NGNE N/A
- EPS
- OCGN N/A
- NGNE N/A
- Revenue
- OCGN $4,522,000.00
- NGNE $925,000.00
- Revenue This Year
- OCGN N/A
- NGNE N/A
- Revenue Next Year
- OCGN N/A
- NGNE N/A
- P/E Ratio
- OCGN N/A
- NGNE N/A
- Revenue Growth
- OCGN N/A
- NGNE N/A
- 52 Week Low
- OCGN $0.52
- NGNE $6.88
- 52 Week High
- OCGN $1.98
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- OCGN 55.00
- NGNE 40.98
- Support Level
- OCGN $0.95
- NGNE $19.13
- Resistance Level
- OCGN $1.15
- NGNE $18.21
- Average True Range (ATR)
- OCGN 0.11
- NGNE 1.59
- MACD
- OCGN -0.02
- NGNE -0.59
- Stochastic Oscillator
- OCGN 22.62
- NGNE 4.26
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.